Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

Fig. 2

PFS according to ERCC1 expression. Patients with moderate or high levels of ERCC1 had shorter progression-free survival [median PFS: 5.1 months, mean PFS ± SE: 6.6 months ±1.3 (95% CI: 4.1–9)] than patients with low or no ERCC1 production [median PFS: 10.2 months, mean PFS ± SE: 15.7 months ±4.8 (95% CI: 6.3–25.2)] (p = 0.027). PFS, Progression Free Survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us